Beyond Barriers

A novel technology platform
for the delivery of therapeutics
across biological barriers

TECHNOLOGY INVESTORS
Gate2Brain

The solution

Gate2Brain
Technology

Gate2Brain (G2B) uses a novel technology platform for the delivery of therapeutics. Our platform is based on three families of peptide shuttles that improve the biopharmaceutical properties of cargoes such as small molecules, peptides, nanoparticles, proteins and antibodies in vitro and in vivo when conjugated to them.

The G2B technology platform is applicable to therapeutic areas in which biological barriers hinder the delivery and activity of drugs.

Read more

About us

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We pursue our goals using a radically innovative peptide-based patented technology platform.

Read more
Link to: Technology
Technology

Gate2Brain (G2B) has a proprietary novel technology platform for the delivery of therapeutics across biological barriers.

Link to: Pipeline-Proof of Concept
Pipeline and Therapeutic Proof of Concept

G2B-002, the first therapeutic proof of concept of our technology platform, is aimed mainly at the treatment of rare pediatric solid tumors.

Link to: Investors
Investors

A strong network of investors ensures funding to achieve our goals.

Medicines beyond barriers

We go beyond physiological and disease barriers, as our portfolio of peptide shuttles cover barriers such as the blood-brain,
blood-retinal, skin and tumor barriers. We go beyond economic barriers, such as the lack of investment for the development of pediatric drugs. We go beyond societal barriers to provide medicines for everyone, everywhere.

Clinical Focus

Therapeutic
Proof of Concept

Our G2B therapeutic-peptide shuttle conjugates carry the drug cargo candidates to the target site in which the disease arises. G2B-002, our flagship product and proof of concept of the technology, offers a new therapeutic approach with improved biopharmaceutical properties and potent activity against rare pediatric cancers.

Our objective is for G2B-002 to reach Phase 1 clinical trials and thus have a high social impact focused on the unmet medical needs of oncology, pediatric and rare diseases.

G2B-002 shows potent preclinical activity for rare pediatric cancer indications such as pediatric high-grade gliomas, DIPG, Ewing sarcoma, rhabdomyosarcoma and neuroblastoma.

READ MORE
Gate2Brain

News & Media

Welcome to our news section, which provides a selection of our coverage in the media, industry, latest developments, plus videos, and more.

BIO-EUROPE STOCKHOLM

Gate2Brain will be attending Bio-Europe 2024 from the 4th to 6th November 2024, in Stockholm, Sweden. Would…
Read more

Gate2Brain 4-Year Journey

Our special annual magazine, which takes you through the 4-year journey of Gate2Brain …
Read more

Gate2Brain is attending BioJapan 2024

From October 9th to 11th, Gate2Brain will proudly join the Catalan delegation, organized by Biocat…
Read more

Jump4Women – Trip to Boston

,
We are incredibly honored to have been part of a group of 19 women entrepreneurs who recently traveled…
Read more

Gate2Brain is Virtually Partnering at RESIBOSTON!

After winning the IPC challenge pitch at RESI BCN, here we are! Discover our groundbreaking…
Read more

Gate2Brain’s Summer Retreat 2024

Just before heading off for the holidays at the end of July, the Gate2Brain family came together…
Read more

Back to Work with Peptides

,
  These late August days have been busy for us as we've been attending two peptide conferences.…
Read more

Fernando Albericio – Meet the Advisory Board

, ,
We are continuing to introduce the remarkable individuals who make up Gate2Brain’s external advisory…
Read more

Breaking Barriers in Science: The Journey of Meritxell Teixidó and Gate2Brain

,
Interview with Meritxell Teixidó, PhD, CEO & CSO, Gate2Brain By Caitlin Dolegowski, Marketing Manager,…
Read more

Gate2Brain and Intact Barrier Brain Tumors: A Ray of Hope in the Fight against DIPG

On the occasion of World Brain Day Meritxell Teixidó, CEO & CSO of Gate2Brain, analyzes the scientific…
Read more
NEWS & MEDIA
1
2
Gate2Brain
1

Making therapies a reality for patients by addressing unmet medical needs.

2

Improving patients’ quality of life using a technology that provides superior drug transport efficacy.

Go Beyond Barriers & Contact Us

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain
Gate2Brain

Gate2Brain is a biotech company focused on the development of therapeutics that efficiently cross biological barriers such as the blood-brain barrier. We use a radically innovative peptide-based patented technology.

Where to find us

Barcelona Scientific Park
Baldiri Reixac, 4-8, Torre I
08028 Barcelona, Spain
info@gate2brain.com

Social